In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response. Understanding how ...
Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer. Kaakour is ...
The FDA has approved a label update for nadofaragene firadenovec-vncg (Adstiladrin), introducing an accelerated thawing protocol that may reduce preparation time for intravesical administration of the ...
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant ...
Sarah Azari, MD, highlights a prospective study examining the impact of perioperative education on demoralization and sexual function in women with bladder cancer.
The Genomic Prostate Score (GPS) is being validated in the ProtecT trial to predict prostate cancer progression and treatment outcomes. ProtecT is a landmark phase 3 trial with over 1600 men, ...
The Vanquish Water Vapor System and Hugo robotic-assisted surgery system received FDA clearance for prostate cancer and urologic procedures, respectively, demonstrating high effectiveness and safety.
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results